Sinopharm 

HK$16.82
43
-HK$0.24-1.41% Thursday 08:08

Statistik

Dagens högsta
17.3
Dagens lägsta
16.68
52V högsta
23
52V lägsta
16.68
Volym
10,652,566
Genomsnittlig volym
5,532,884
Marknadsvärde
63.51B
P/E förhållande
7.22
Utdelningsavkastning
5.68%
Utdelning
0.96

Kommande

Utdelningar

5.68%Utdelningsavkastning
10-års tillväxt
11.31%
5 års tillväxt
7.33%
3 års tillväxt
4.43%
1 års tillväxt
6.09%

Inkomster

25AugFörväntad
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
0.69
1.04
1.4
1.75
Förväntad EPS
1.4800067469359999
Verklig EPS
1.2762377020679998

Människor följer också

Den här listan baseras på bevakningslistorna för människor på Stock Events som följer 1099.HK. Det är inte en investeringsrekommendation.

Konkurrenter

Denna lista är en analys baserad på nyliga marknadshändelser. Det är inte en investeringsrekommendation.

Om

Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Show more...
VD
Mr. Qingming Yu
Anställda
113234
Land
Hong Kong
ISIN
CNE100000FN7

Noteringar